Advanced Prostate Cancer VL

A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer - Beyond the Abstract

Details
We conducted a study to assess the safety and efficacy of relugolix combined with abiraterone acetate or apalutamide. We presented results from this ongoing, two-part, Phase I, 52-week, open-label cohort study in patients with advanced prostate cancer (NCT04666129), which evaluated relugolix in combination with abiraterone acetate and a corticosteroid (prednisone or methylprednisolone) in Part 1,...

Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines for advanced prostate cancer, focusing on triplet therapy for metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castrate-resistant prostate cancer (M0 CRPC). They delve into the role of triplet therapy in mHSPC, examining its benefits across disease volume and risk subgroups, as evidenced by the ARASENS and PE...

Apalutamide plus Androgen Deprivation Therapy in Clinical Subgroups of Patients with Metastatic Castration-Sensitive Prostate Cancer: A Subgroup Analysis of the Randomised Clinical TITAN Study - Beyon...

Details
Whether disease burden in patients with metastatic castration-sensitive prostate cancer (mCSPC) predicts treatment outcomes is unknown. We assessed apalutamide treatment effect in TITAN patients with mCSPC by disease volume, metastasis number and timing of metastasis presentation. Biographies: Axel S. Merseburger, MD, PhD, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany Rela...

Novel Biomarker Analysis Reveals SPOP Gene Mutation Unlocks Sensitivity to PARP Inhibitor Treatment in Metastatic Castration-Resistant Prostate Cancer - Emmanuel Antonarakis & Jacob Orme

Details
Jacob Orme and Emmanuel Antonarakis discuss their study on the use of PARP inhibitors in metastatic prostate cancer patients with BRCA2 and SPOP mutations. Dr. Antonarakis shares the study's genesis, rooted in his clinical observation of exceptional responses to PARP inhibitors in patients with these mutations. The study, involving 131 patients across 13 international sites, reveals that patients...

Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic

Details
Andrea hosts Jessica Hawley and Aleksandar Obradovic to discuss their study, published in Cancer Cell, which explores the effects of combining Anti-PD-1 immunotherapy with Androgen Deprivation Therapy (ADT) in metastatic castration-sensitive prostate cancer. The research, part of the PRIME-CUT Study, used advanced techniques like single-cell RNA sequencing and quantitative immunofluorescence to an...

ENZA-p Trial Shows Promise for Enzalutamide-Lutetium Combination in Prostate Cancer - Louise Emmett

Details
Alicia Morgans speaks with Louise Emmett about the ENZA-p study, presented at ESMO 2023. This groundbreaking research explores the combination of lutetium and enzalutamide in treating early metastatic castrate-resistant prostate cancer. Patients, previously showing limited response to enzalutamide, were screened with PSMA PET and randomized to receive either enzalutamide alone or combined with lut...

Harnessing Tumor Biology to Improve Outcomes in Advanced Hormone-Sensitive Prostate Cancer - Gerhardt Attard

Details
Gerhardt Attard discusses advancing the treatment of advanced hormone-sensitive prostate cancer through biological research. Dr. Attard's work focuses on two main areas: analyzing tumor samples from clinical trials to understand the biology driving cancer aggressiveness and identifying new therapeutic targets. He emphasizes the need for prognostic tests to tailor treatments, especially considering...

Novel STEAP1 Targeted BiTE Therapy Demonstrates Early Efficacy in Phase 1 Trial - William Kevin Kelly

Details
Kevin Kelly discusses a groundbreaking approach to prostate cancer treatment with Alicia Morgans. He presents Xaluritamig (AMG 509) a novel bi-specific antibody targeting the STEAP1 protein, prevalent in prostate cancer cells. This innovative therapy, a form of biTE therapy, is designed to attract T-cells for targeted cytotoxicity. In a phase one trial involving advanced prostate cancer patients w...

Shifting Clinical Trial Design Towards Improving Patient Enrollment - Michael Morris

Details
Alicia Morgans engages with Michael Morris to discuss the transformation of clinical trial design to improve patient access and applicability of results. Dr. Morris highlights the complexity of current clinical trials, which often involve extensive documentation and stringent eligibility criteria, limiting participation to a narrow patient population and placing a heavy burden on both participants...

AMG 509's Potential in Prostate Cancer Therapy - Michael Morris

Details
Michael Morris highlights notable prostate cancer trials, focusing on AMG 509, a bispecific antibody targeting STEAP1 and CD3. This promising early-phase study, still determining optimal dosages, shows potential in treating prostate cancer, a field historically resistant to immune therapy. Dr. Morris emphasizes AMG 509's ability to reduce bony and visceral diseases, including liver disease, with m...